Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia.

Pouliot GP, Degar J, Hinze L, Kochupurakkal B, Vo CD, Burns MA, Moreau L, Ganesa C, Roderick J, Peirs S, Menten B, Loh ML, Hunger SP, Silverman LB, Harris MH, Stevenson KE, Weinstock DM, Weng AP, Van Vlierberghe P, D'Andrea AD, Gutierrez A.

PLoS One. 2019 Nov 13;14(11):e0221288. doi: 10.1371/journal.pone.0221288. eCollection 2019.

2.

ZEB2 in T-cells and T-ALL.

De Coninck S, Berx G, Taghon T, Van Vlierberghe P, Goossens S.

Adv Biol Regul. 2019 Dec;74:100639. doi: 10.1016/j.jbior.2019.100639. Epub 2019 Jul 27. Review.

PMID:
31383581
3.

Targeting steroid resistance in T-cell acute lymphoblastic leukemia.

De Smedt R, Morscio J, Goossens S, Van Vlierberghe P.

Blood Rev. 2019 Nov;38:100591. doi: 10.1016/j.blre.2019.100591. Epub 2019 Jul 19. Review.

PMID:
31353059
4.

Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies.

Pieters T, T'Sas S, Demoen L, Almeida A, Haenebalcke L, Matthijssens F, Lemeire K, D'Hont J, Van Rockeghem F, Hochepied T, Lintermans B, Reunes L, Lammens T, Berx G, Haigh JJ, Goossens S, Van Vlierberghe P.

Sci Rep. 2019 Jul 22;9(1):10577. doi: 10.1038/s41598-019-46853-x.

5.

Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL).

Hofmans M, Suciu S, Ferster A, Van Vlierberghe P, Mazingue F, Sirvent N, Costa V, Yakouben K, Paillard C, Uyttebroeck A, Plantaz D, Plat G, Simon P, Millot F, Poirée M, van der Werff Ten Bosch J, Piette C, Minckes O, Rohrlich P, Girard S, Cavé H, Bertrand Y, De Moerloose B.

Br J Haematol. 2019 Sep;186(5):741-753. doi: 10.1111/bjh.15983. Epub 2019 May 24.

6.

Corrigendum: Xenopus tropicalis: Joining the Armada in the Fight Against Blood Cancer.

Dimitrakopoulou D, Tulkens D, Van Vlierberghe P, Vleminckx K.

Front Physiol. 2019 Mar 14;10:210. doi: 10.3389/fphys.2019.00210. eCollection 2019.

7.

Xenopus tropicalis: Joining the Armada in the Fight Against Blood Cancer.

Dimitrakopoulou D, Tulkens D, Van Vlierberghe P, Vleminckx K.

Front Physiol. 2019 Feb 1;10:48. doi: 10.3389/fphys.2019.00048. eCollection 2019. Erratum in: Front Physiol. 2019 Mar 14;10:210.

8.

ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms.

Goossens S, Wang J, Tremblay CS, De Medts J, T'Sas S, Nguyen T, Saw J, Haigh K, Curtis DJ, Van Vlierberghe P, Berx G, Taghon T, Haigh JJ.

Haematologica. 2019 Aug;104(8):1608-1616. doi: 10.3324/haematol.2018.207837. Epub 2019 Jan 24.

9.

PTEN abnormalities predict poor outcome in children with T-cell acute lymphoblastic leukemia treated according to ALL IC-BFM protocols.

Szarzyńska-Zawadzka B, Kunz JB, Sędek Ł, Kosmalska M, Zdon K, Biecek P, Bandapalli OR, Kraszewska-Hamilton M, Jaksik R, Drobna M, Kowalczyk JR, Szczepański T, Van Vlierberghe P, Kulozik AE, Witt M, Dawidowska M.

Am J Hematol. 2019 Apr;94(4):E93-E96. doi: 10.1002/ajh.25396. Epub 2019 Jan 24. No abstract available.

PMID:
30614545
10.

Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL.

Wendorff AA, Quinn SA, Rashkovan M, Madubata CJ, Ambesi-Impiombato A, Litzow MR, Tallman MS, Paietta E, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Rabadan R, Van Vlierberghe P, Ferrando AA.

Cancer Discov. 2019 Mar;9(3):436-451. doi: 10.1158/2159-8290.CD-18-1005. Epub 2018 Dec 19.

PMID:
30567843
11.

T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development.

de Bock CE, Down M, Baidya K, Sweron B, Boyd AW, Fiers M, Burns GF, Molloy TJ, Lock RB, Soulier J, Taghon T, Van Vlierberghe P, Cools J, Holst J, Thorne RF.

Haematologica. 2019 May;104(5):e204-e207. doi: 10.3324/haematol.2018.198424. Epub 2018 Dec 4. No abstract available.

12.

PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.

Ariës IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, Pfirrmann M, Degar J, Landrigan JT, Balbach S, Peirs S, Menten B, Isenhart R, Stevenson KE, Neuberg DS, Devidas M, Loh ML, Hunger SP, Teachey DT, Rabin KR, Winter SS, Dunsmore KP, Wood BL, Silverman LB, Sallan SE, Van Vlierberghe P, Orkin SH, Knoechel B, Letai AG, Gutierrez A.

J Exp Med. 2018 Dec 3;215(12):3094-3114. doi: 10.1084/jem.20180570. Epub 2018 Nov 7.

13.

SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival.

Su H, Hu J, Huang L, Yang Y, Thenoz M, Kuchmiy A, Hu Y, Li P, Feng H, Zhou Y, Taghon T, Van Vlierberghe P, Qing G, Chen Z, Liu H.

Nat Commun. 2018 Oct 15;9(1):4281. doi: 10.1038/s41467-018-06523-4.

14.

A Novel t(8;14)(q24;q11) Rearranged Human Cell Line as a Model for Mechanistic and Drug Discovery Studies of NOTCH1-Independent Human T-Cell Leukemia.

Tosello V, Milani G, Martines A, Macri N, Van Loocke W, Matthijssens F, Buldini B, Minuzzo S, Bongiovanni D, Schumacher RF, Amadori A, Van Vlierberghe P, Piovan E.

Cells. 2018 Oct 9;7(10). pii: E160. doi: 10.3390/cells7100160.

15.

Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation.

Gachet S, El-Chaar T, Avran D, Genesca E, Catez F, Quentin S, Delord M, Thérizols G, Briot D, Meunier G, Hernandez L, Pla M, Smits WK, Buijs-Gladdines JG, Van Loocke W, Menschaert G, André-Schmutz I, Taghon T, Van Vlierberghe P, Meijerink JP, Baruchel A, Dombret H, Clappier E, Diaz JJ, Gazin C, de Thé H, Sigaux F, Soulier J.

Cancer Discov. 2018 Dec;8(12):1614-1631. doi: 10.1158/2159-8290.CD-17-0831. Epub 2018 Sep 28.

16.

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD.

Leukemia. 2018 Dec;32(12):2731. doi: 10.1038/s41375-018-0241-7.

PMID:
30232463
17.

USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia.

Jin Q, Martinez CA, Arcipowski KM, Zhu Y, Gutierrez-Diaz BT, Wang KK, Johnson MR, Volk AG, Wang F, Wu J, Grove C, Wang H, Sokirniy I, Thomas PM, Goo YA, Abshiru NA, Hijiya N, Peirs S, Vandamme N, Berx G, Goosens S, Marshall SA, Rendleman EJ, Takahashi YH, Wang L, Rawat R, Bartom ET, Collings CK, Van Vlierberghe P, Strikoudis A, Kelly S, Ueberheide B, Mantis C, Kandela I, Bourquin JP, Bornhauser B, Serafin V, Bresolin S, Paganin M, Accordi B, Basso G, Kelleher NL, Weinstock J, Kumar S, Crispino JD, Shilatifard A, Ntziachristos P.

Clin Cancer Res. 2019 Jan 1;25(1):222-239. doi: 10.1158/1078-0432.CCR-18-1740. Epub 2018 Sep 17.

PMID:
30224337
18.

Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, Lintermans B, Goossens S, Lammens T, Van Roy N, Touzart A, Jenni S, Tsai YC, Lovisa F, Mussolin L, Serafin V, Van Nieuwerburgh F, Deforce D, Uyttebroeck A, Tousseyn T, Burkhardt B, Klapper W, De Moerloose B, Benoit Y, Macintyre E, Bourquin JP, Basso G, Accordi B, Bornhauser B, Meijerink J, Vandenberghe P, Van Vlierberghe P.

Haematologica. 2019 Jan;104(1):e17-e20. doi: 10.3324/haematol.2018.199257. Epub 2018 Aug 3. No abstract available.

19.

A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing.

Verboom K, Van Loocke W, Volders PJ, Decaesteker B, Cobos FA, Bornschein S, de Bock CE, Atak ZK, Clappier E, Aerts S, Cools J, Soulier J, Taghon T, Van Vlierberghe P, Vandesompele J, Speleman F, Durinck K.

Haematologica. 2018 Dec;103(12):e585-e589. doi: 10.3324/haematol.2018.190587. Epub 2018 Jun 28. No abstract available.

20.

Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia.

Milani G, Matthijssens F, Van Loocke W, Durinck K, Roels J, Peirs S, Thénoz M, Pieters T, Reunes L, Lintermans B, Vandamme N, Lammens T, Van Roy N, Van Nieuwerburgh F, Deforce D, Schwab C, Raimondi S, Dalla Pozza L, Carroll AJ 3rd, De Moerloose B, Benoit Y, Goossens S, Berx G, Harrison CJ, Basso G, Cavé H, Sutton R, Asnafi V, Meijerink J, Mullighan C, Loh M, Van Vlierberghe P.

Br J Haematol. 2019 Apr;185(1):169-174. doi: 10.1111/bjh.15425. Epub 2018 Jun 25. No abstract available.

PMID:
29938777
21.

The long non-coding RNA landscape in juvenile myelomonocytic leukemia.

Hofmans M, Lammens T, Helsmoortel HH, Bresolin S, Cavé H, Flotho C, Hasle H, van den Heuvel-Eibrink MM, Niemeyer C, Stary J, Van Roy N, Van Vlierberghe P, Philippé J, De Moerloose B.

Haematologica. 2018 Nov;103(11):e501-e504. doi: 10.3324/haematol.2018.189977. Epub 2018 Jun 1. No abstract available.

22.

Expressed repetitive elements are broadly applicable reference targets for normalization of reverse transcription-qPCR data in mice.

Renard M, Vanhauwaert S, Vanhomwegen M, Rihani A, Vandamme N, Goossens S, Berx G, Van Vlierberghe P, Haigh JJ, Decaesteker B, Van Laere J, Lambertz I, Speleman F, Vandesompele J, Willaert A.

Sci Rep. 2018 May 16;8(1):7642. doi: 10.1038/s41598-018-25389-6.

23.

ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?

Soen B, Vandamme N, Berx G, Schwaller J, Van Vlierberghe P, Goossens S.

Hemasphere. 2018 May 11;2(3):e43. doi: 10.1097/HS9.0000000000000043. eCollection 2018 Jun. Review.

24.

A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias In Vivo.

Nguyen HA, Su Y, Zhang JY, Antanasijevic A, Caffrey M, Schalk AM, Liu L, Rondelli D, Oh A, Mahmud DL, Bosland MC, Kajdacsy-Balla A, Peirs S, Lammens T, Mondelaers V, De Moerloose B, Goossens S, Schlicht MJ, Kabirov KK, Lyubimov AV, Merrill BJ, Saunthararajah Y, Van Vlierberghe P, Lavie A.

Cancer Res. 2018 Mar 15;78(6):1549-1560. doi: 10.1158/0008-5472.CAN-17-2106. Epub 2018 Jan 17.

25.

LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis.

El Ashkar S, Schwaller J, Pieters T, Goossens S, Demeulemeester J, Christ F, Van Belle S, Juge S, Boeckx N, Engelman A, Van Vlierberghe P, Debyser Z, De Rijck J.

Blood. 2018 Jan 4;131(1):95-107. doi: 10.1182/blood-2017-05-786962. Epub 2017 Oct 30.

26.

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD.

Leukemia. 2018 Mar;32(3):788-800. doi: 10.1038/leu.2017.276. Epub 2017 Aug 30. Erratum in: Leukemia. 2018 Dec;32(12):2731.

27.

Comprehensive miRNA expression profiling in human T-cell acute lymphoblastic leukemia by small RNA-sequencing.

Wallaert A, Van Loocke W, Hernandez L, Taghon T, Speleman F, Van Vlierberghe P.

Sci Rep. 2017 Aug 11;7(1):7901. doi: 10.1038/s41598-017-08148-x.

28.

Digital Multiplex Ligation-Dependent Probe Amplification for Detection of Key Copy Number Alterations in T- and B-Cell Lymphoblastic Leukemia.

Benard-Slagter A, Zondervan I, de Groot K, Ghazavi F, Sarhadi V, Van Vlierberghe P, De Moerloose B, Schwab C, Vettenranta K, Harrison CJ, Knuutila S, Schouten J, Lammens T, Savola S.

J Mol Diagn. 2017 Sep;19(5):659-672. doi: 10.1016/j.jmoldx.2017.05.004. Epub 2017 Jul 19.

29.

EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET.

Goossens S, Vandamme N, Van Vlierberghe P, Berx G.

Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):584-591. doi: 10.1016/j.bbcan.2017.06.006. Epub 2017 Jun 29. Review.

PMID:
28669750
30.

Novel oncogenic noncoding mutations in T-ALL.

Goossens S, Van Vlierberghe P.

Blood. 2017 Jun 15;129(24):3140-3142. doi: 10.1182/blood-2017-04-773242. No abstract available.

PMID:
28620102
31.

Long non-coding RNAs in leukemia: biology and clinical impact.

Lammens T, Durinck K, Wallaert A, Speleman F, Van Vlierberghe P.

Curr Opin Hematol. 2017 Jul;24(4):353-358. doi: 10.1097/MOH.0000000000000354. Review.

PMID:
28441150
32.

T-ALL and thymocytes: a message of noncoding RNAs.

Wallaert A, Durinck K, Taghon T, Van Vlierberghe P, Speleman F.

J Hematol Oncol. 2017 Mar 7;10(1):66. doi: 10.1186/s13045-017-0432-0. Review.

33.

Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.

Peirs S, Frismantas V, Matthijssens F, Van Loocke W, Pieters T, Vandamme N, Lintermans B, Dobay MP, Berx G, Poppe B, Goossens S, Bornhauser BC, Bourquin JP, Van Vlierberghe P.

Leukemia. 2017 Oct;31(10):2037-2047. doi: 10.1038/leu.2017.10. Epub 2017 Jan 11.

34.

Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia.

Goossens S, Peirs S, Van Loocke W, Wang J, Takawy M, Matthijssens F, Sonderegger SE, Haigh K, Nguyen T, Vandamme N, Costa M, Carmichael C, Van Nieuwerburgh F, Deforce D, Kleifeld O, Curtis DJ, Berx G, Van Vlierberghe P, Haigh JJ.

Blood. 2017 Feb 23;129(8):981-990. doi: 10.1182/blood-2016-06-721191. Epub 2017 Jan 9.

35.

Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia.

Goossens S, Van Vlierberghe P.

PLoS Med. 2016 Dec 20;13(12):e1002208. doi: 10.1371/journal.pmed.1002208. eCollection 2016 Dec.

36.

Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia.

Ghazavi F, De Moerloose B, Van Loocke W, Wallaert A, Helsmoortel HH, Ferster A, Bakkus M, Plat G, Delabesse E, Uyttebroeck A, Van Nieuwerburgh F, Deforce D, Van Roy N, Speleman F, Benoit Y, Lammens T, Van Vlierberghe P.

Oncotarget. 2016 Nov 8;7(45):73769-73780. doi: 10.18632/oncotarget.12063.

37.

A quantitative proteomics approach identifies ETV6 and IKZF1 as new regulators of an ERG-driven transcriptional network.

Unnikrishnan A, Guan YF, Huang Y, Beck D, Thoms JA, Peirs S, Knezevic K, Ma S, de Walle IV, de Jong I, Ali Z, Zhong L, Raftery MJ, Taghon T, Larsson J, MacKenzie KL, Van Vlierberghe P, Wong JW, Pimanda JE.

Nucleic Acids Res. 2016 Dec 15;44(22):10644-10661. Epub 2016 Sep 6.

38.

Long noncoding RNA signatures define oncogenic subtypes in T-cell acute lymphoblastic leukemia.

Wallaert A, Durinck K, Van Loocke W, Van de Walle I, Matthijssens F, Volders PJ, Avila Cobos F, Rombaut D, Rondou P, Mestdagh P, Vandesompele J, Poppe B, Taghon T, Soulier J, Van Vlierberghe P, Speleman F.

Leukemia. 2016 Sep;30(9):1927-30. doi: 10.1038/leu.2016.82. Epub 2016 Apr 22. No abstract available.

PMID:
27168467
39.

GATA3 induces human T-cell commitment by restraining Notch activity and repressing NK-cell fate.

Van de Walle I, Dolens AC, Durinck K, De Mulder K, Van Loocke W, Damle S, Waegemans E, De Medts J, Velghe I, De Smedt M, Vandekerckhove B, Kerre T, Plum J, Leclercq G, Rothenberg EV, Van Vlierberghe P, Speleman F, Taghon T.

Nat Commun. 2016 Apr 6;7:11171. doi: 10.1038/ncomms11171.

40.

LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19.

Helsmoortel HH, De Moerloose B, Pieters T, Ghazavi F, Bresolin S, Cavé H, de Vries A, de Haas V, Flotho C, Labarque V, Niemeyer C, De Paepe P, Van Roy N, Stary J, van den Heuvel-Eibrink MM, Benoit Y, Schulte J, Goossens S, Berx G, Haigh JJ, Speleman F, Van Vlierberghe P, Lammens T.

Haematologica. 2016 Jun;101(6):e240-4. doi: 10.3324/haematol.2016.143818. Epub 2016 Mar 11. No abstract available.

41.

LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia.

Helsmoortel HH, Bresolin S, Lammens T, Cavé H, Noellke P, Caye A, Ghazavi F, de Vries A, Hasle H, Labarque V, Masetti R, Stary J, van den Heuvel-Eibrink MM, Philippé J, Van Roy N, Benoit Y, Speleman F, Niemeyer C, Flotho C, Basso G, Te Kronnie G, Van Vlierberghe P, De Moerloose B.

Blood. 2016 Mar 3;127(9):1163-72. doi: 10.1182/blood-2015-09-667808. Epub 2015 Dec 28.

PMID:
26712910
42.

CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol.

Ghazavi F, Clappier E, Lammens T, Suciu S, Caye A, Zegrari S, Bakkus M, Grardel N, Benoit Y, Bertrand Y, Minckes O, Costa V, Ferster A, Mazingue F, Plat G, Plouvier E, Poirée M, Uyttebroeck A, van der Werff-Ten Bosch J, Yakouben K, Helsmoortel H, Meul M, Van Roy N, Philippé J, Speleman F, Cavé H, Van Vlierberghe P, De Moerloose B.

Haematologica. 2015 Oct;100(10):1311-9. doi: 10.3324/haematol.2015.126953. Epub 2015 Jul 2.

43.

Novel biological insights in T-cell acute lymphoblastic leukemia.

Durinck K, Goossens S, Peirs S, Wallaert A, Van Loocke W, Matthijssens F, Pieters T, Milani G, Lammens T, Rondou P, Van Roy N, De Moerloose B, Benoit Y, Haigh J, Speleman F, Poppe B, Van Vlierberghe P.

Exp Hematol. 2015 Aug;43(8):625-39. doi: 10.1016/j.exphem.2015.05.017. Epub 2015 Jun 26. Review.

PMID:
26123366
44.

Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia.

Durinck K, Van Loocke W, Van der Meulen J, Van de Walle I, Ongenaert M, Rondou P, Wallaert A, de Bock CE, Van Roy N, Poppe B, Cools J, Soulier J, Taghon T, Speleman F, Van Vlierberghe P.

Leukemia. 2015 Dec;29(12):2317-27. doi: 10.1038/leu.2015.162. Epub 2015 Jun 25.

PMID:
26108691
45.

Molecular basis and clinical significance of genetic aberrations in B-cell precursor acute lymphoblastic leukemia.

Ghazavi F, Lammens T, Van Roy N, Poppe B, Speleman F, Benoit Y, Van Vlierberghe P, De Moerloose B.

Exp Hematol. 2015 Aug;43(8):640-53. doi: 10.1016/j.exphem.2015.05.015. Epub 2015 Jun 20. Review.

PMID:
26101161
46.

ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling.

Goossens S, Radaelli E, Blanchet O, Durinck K, Van der Meulen J, Peirs S, Taghon T, Tremblay CS, Costa M, Farhang Ghahremani M, De Medts J, Bartunkova S, Haigh K, Schwab C, Farla N, Pieters T, Matthijssens F, Van Roy N, Best JA, Deswarte K, Bogaert P, Carmichael C, Rickard A, Suryani S, Bracken LS, Alserihi R, Canté-Barrett K, Haenebalcke L, Clappier E, Rondou P, Slowicka K, Huylebroeck D, Goldrath AW, Janzen V, McCormack MP, Lock RB, Curtis DJ, Harrison C, Berx G, Speleman F, Meijerink JP, Soulier J, Van Vlierberghe P, Haigh JJ.

Nat Commun. 2015 Jan 7;6:5794. doi: 10.1038/ncomms6794.

47.

Controlling pre-leukemic thymocyte self-renewal.

Goossens S, Van Vlierberghe P.

PLoS Genet. 2014 Dec 18;10(12):e1004881. doi: 10.1371/journal.pgen.1004881. eCollection 2014 Dec. No abstract available.

48.

Epigenetics in T-cell acute lymphoblastic leukemia.

Peirs S, Van der Meulen J, Van de Walle I, Taghon T, Speleman F, Poppe B, Van Vlierberghe P.

Immunol Rev. 2015 Jan;263(1):50-67. doi: 10.1111/imr.12237. Review.

PMID:
25510271
49.

Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia.

Sanghvi VR, Mavrakis KJ, Van der Meulen J, Boice M, Wolfe AL, Carty M, Mohan P, Rondou P, Socci ND, Benoit Y, Taghon T, Van Vlierberghe P, Leslie CS, Speleman F, Wendel HG.

Sci Signal. 2014 Nov 18;7(352):ra111. doi: 10.1126/scisignal.2005500.

50.

The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.

Durinck K, Wallaert A, Van de Walle I, Van Loocke W, Volders PJ, Vanhauwaert S, Geerdens E, Benoit Y, Van Roy N, Poppe B, Soulier J, Cools J, Mestdagh P, Vandesompele J, Rondou P, Van Vlierberghe P, Taghon T, Speleman F.

Haematologica. 2014 Dec;99(12):1808-16. doi: 10.3324/haematol.2014.115683. Epub 2014 Oct 24.

Supplemental Content

Loading ...
Support Center